The transactivation of EGFR by GPCR agonism is well-described and known to cause downstream activation of MEK/ERK1/2 MAP kinase pathways, which in turn influence invasion and migration capacities of tumor cells [34–37]. The gene discussed is EGFR; the disease is neoplasm.